GPNMB is a biomarker for lysosomal dysfunction and is secreted via LRRK2-modulated lysosomal exocytosis
Science Advances · 2025
DOI: 10.1126/sciadv.adv1434 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Advances, 2025. Verfasst von Erin C Bogacki und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Comparative Biomedical Sciences, Royal Veterinary College, Camden, NW1 0TU, UK. Hauptthemen laut MEDLINE: Lysosomes, Leucine-Rich Repeat Serine-Threonine Protein Kinase-2, Exocytosis, Membrane Glycoproteins. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Michael J. Fox Foundation for Parkinson's Research, UCLH NIHR Biomedical Research Centre, Aligning Science Across Parkinson.
Abstract (Originalsprache)
Genome-wide association studies have identified Glycoprotein Nmb ( GPNMB ) as a risk factor for Parkinson’s disease. The risk allele increases GPNMB transcription and GPNMB protein levels in the CSF highlighting GPMNB as a potential biomarker for Parkinson’s disease. However, a lack of knowledge of GPNMB’s function and mechanism of secretion has hindered an interpretation of secreted GPNMB levels. In this study, we assessed the mechanism of GPNMB secretion by macrophages, the primary cell type expressing GPNMB in the brain. We show that GPNMB is secreted in response to lysosomal stress via lysosomal exocytosis and highlight the Parkinson’s disease risk factor LRRK2 as a strong modulator of GPNMB secretion.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Comparative Biomedical Sciences, Royal Veterinary College, Camden, NW1 0TU, UK.
- Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, WC1N 3BG, UK.
- Aligning Science Across Parkinson's Research Network, Chevy Chase, MD 20815, USA.
ORCID-Profile: Erin C Bogacki, Gustavo Morrone Parfitt, Adriana Cunha, George Longmore, Patrick A Lewis, Susanne Herbst
Förderung
- Michael J. Fox Foundation for Parkinson's Research
- UCLH NIHR Biomedical Research Centre
- Aligning Science Across Parkinson
Zitieren
APA
Bogacki, E. C., Parfitt, G. M., Cunha, A., Longmore, G., Wray, S., Lewis, P. A., & Herbst, S. (2025). GPNMB is a biomarker for lysosomal dysfunction and is secreted via LRRK2-modulated lysosomal exocytosis. Science Advances. https://doi.org/10.1126/sciadv.adv1434
Vancouver
Bogacki EC, Parfitt GM, Cunha A, Longmore G, Wray S, Lewis PA, et al. GPNMB is a biomarker for lysosomal dysfunction and is secreted via LRRK2-modulated lysosomal exocytosis. Science Advances. 2025. doi:10.1126/sciadv.adv1434
BibTeX
@article{Bogacki2025,
author = {Bogacki, Erin C and Parfitt, Gustavo Morrone and Cunha, Adriana and Longmore, George and Wray, Selina and Lewis, Patrick A and Herbst, Susanne},
title = {GPNMB is a biomarker for lysosomal dysfunction and is secreted via LRRK2-modulated lysosomal exocytosis},
journal = {Science Advances},
year = {2025},
doi = {10.1126/sciadv.adv1434}
}
EUVIMED